Physician profile
John Robert Nienow
NPI 1861472649
$20,195.71
in general payments reported to CMS, 2019-2025
8 companies · $1,869 in 2025
The $1,869 reported for 2025 was more than what 85% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,485 · 2020: $5,515 · 2021: $482 · 2022: $1,007 · 2023: $1,224 · 2024: $6,614 · 2025: $1,869.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,470 · Food and Beverage: $3,846 · Travel and Lodging: $1,373 · Education: $17.36.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,470.00 |
| Food and Beverage | $3,846.10 |
| Travel and Lodging | $1,372.57 |
| Education | $17.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $11,297.93 | 2019-2025 | Biktarvy |
| Viiv Healthcare Company | $5,951.07 | 2019-2025 | Cabenuva, Dovato, Apretude |
| Emd Serono, INC. | $1,610.76 | 2020-2025 | Serostim |
| Theratechnologies INC. | $931.71 | 2020-2024 | Egrifta, Trogarzo |
| Janssen Biotech, INC. | $185.20 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $178.05 | 2019-2023 | Pifeltro, Delstrigo |
| Glaxosmithkline, LLC. | $26.52 | 2020 | |
| Astellas Pharma US INC | $14.47 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Nienow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.